What is TRAX's market cap?

$1.89B, based on the Nov 2 close of $45.05.

Does First Tracks Biotherapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of TRAX is sold short?

7.0M shares, 21.3% of float, as of Oct 15, 2026.

What sector is TRAX in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · TRAXHealthcarePharmaceuticals

First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX)

$45.05−0.07%

Close Nov 2, 2026 · split-adjusted

Nov 2, 2026$45.05▲ 23.63% in range

Sep 11, 2026Low $30.59 · High $45.72Nov 2, 2026

What changed · written from our data

As of Nov 2, 2026

First Tracks Biotherapeutics closed at $45.05 on Nov 2, down 0.07%, 1.5% below its highest close since Sep 11. Volume of 426.4K shares was 0.36× its 20-day average (below normal).

Split-adjusted performance: +35.4% over one month.

Short interest was 7.0M shares at the Oct 15 settlement, up 34.0% from the prior report (21.3% of float, 4.8 days to cover).

Market cap$1.89B42.0M shares

Revenue · quarter$0.00—

Diluted EPS$-0.95—

P/E · TTM—

Net margin—

Dividend yieldNone

Range since Sep 1130.59 – 45.72−1.5% from high

Volume426.4K0.36× 20-day avg

Volatility · 60d—Annualised

Short % of float21.3%4.8 days to cover

Net cash$168.0MCash $168.0M

Next earnings—Not scheduled

Split-adjusted performance

1W +3.6%1M +35.4%3M —6M —YTD —1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size80

Industry medians: 6-month return −25.1%, revenue growth +6.4%, net margin −36.2%, P/E 15.8×.

Short interest

Details →

Shares short7.0M+34.0% vs prior

Days to cover4.8Settled Oct 15

% of float21.3%

Short vol. 10d53.2%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
TRAXFirst Tracks Biotherapeutics	$45.05	−0.07%	—	—	—	—	$1.89B
BRVEBraveheart Bio	$21.04	−2.19%	—	—	—	—	$1.89B	Compare
XERSXeris Biopharma Holdings	$10.17	−5.04%	+60.4%	+28.7%	−33.8%	—	$1.85B	Compare
SRPTSarepta Therapeutics,	$18.32	−1.61%	−16.9%	−34.3%	−1.2%	—	$1.94B	Compare
TRVITrevi Therapeutics	$13.63	+0.52%	−5.2%	—	—	—	$1.94B	Compare
PGENPrecigen	$5.14	−25.94%	+24.2%	+6322.7%	36.5%	—	$1.84B	Compare
SDGRSchrodinger	$26.19	−3.50%	+103.0%	+7.5%	10.1%	—	$1.96B	Compare
ZBIOZenas BioPharma	$27.62	−2.71%	+28.1%	—	−11145.6%	—	$1.80B	Compare
AGIOAgios Pharmaceuticals	$29.95	−1.96%	+8.7%	+259.3%	−225.1%	—	$1.79B	Compare

News about First Tracks Biotherapeutics

All news →

No recent articles focused on First Tracks Biotherapeutics.

Quick answers

What does First Tracks Biotherapeutics do?: First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial.
What is TRAX's market cap?: $1.89B, based on the Nov 2 close of $45.05.
Does First Tracks Biotherapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of TRAX is sold short?: 7.0M shares, 21.3% of float, as of Oct 15, 2026.
What sector is TRAX in?: Healthcare, in the Pharmaceuticals industry.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

HQ: San Diego, CAListed Apr 6, 2026

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology